Highest-materiality recent filing
Bionano retires all $20M senior secured convertible debentures, eliminating secured debt
Retired $20M in senior secured convertible debentures using cash on hand on May 26, 2026.
Bionano Genomics stockholders elect Luderer and Vuori as directors; pay vote and auditor ratified
Elected Albert Luderer (847,601 for) and Kristiina Vuori (867,474 for) as Class II directors for three-year terms.
Bionano Q1 revenue $6.7M (+4% YoY); gross margin 49%; positive coding updates
Total revenue $6.7M (+4% vs $6.5M Q1 2025); consumables revenue $3.9M (+20%).
Bionano Genomics CEO Erik Holmlin terminated; Chairman Al Luderer named interim CEO
CEO Erik Holmlin terminated effective May 5, 2026; will serve as advisor under consulting agreement.
Bionano Q4 2025 revenue $8.0M (-3% YoY); FY revenue $28.5M (-7%)
Q4 2025 revenue $8.0M vs $8.2M Q4 2024; consumables/software revenue down 1%.
Bionano reports preliminary Q4/FY 2025 revenue down 2-8% YoY; cash $29.6M
Total Q4 revenue $7.8-8.0M, down 2-4% YoY; full-year $28.4-28.6M, down 7-8%.
Bionano Q3 revenue $7.4M (+21% YoY); raises FY 2025 OGM install guidance
Total revenue $7.4M, up 21% from $6.1M in Q3 2024; consumables/software revenue +15%.
Bionano Genomics closes $10M public offering of 5M shares and warrants
Gross proceeds of $10M from sale of 5M shares and Series E/F warrants to purchase up to 10M shares.
Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%
Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.
Bionano Genomics corrects vote counts for Proposals 3 and 4; results unchanged
Corrected Broker Non-Votes for Proposal 3 from 769,744 to 0; no impact on ratification of BDO USA as auditor.
Kristiina Vuori appointed to Audit Committee effective June 10, 2025.
Bionano Q1 revenue $6.5M, down 26% YoY; FY2025 guidance $26-30M
Q1 revenue $6.5M vs $8.8M YoY, down 26%; GAAP gross margin improved to 46% from 32%.
Bionano Genomics Q4 revenue down 24% YoY to $8.2M; full-year revenue $30.8M, down 15%
Q4 2024 revenue $8.2M vs $10.8M in Q4 2023, decline driven by discontinued clinical services; core product revenue 1% higher for full year.
Bionano Genomics enters new $75M ATM sales agreement with H.C. Wainwright, replacing Cowen facility
Terminated prior Cowen sales agreement effective Feb 14, 2025; suspended offering Feb 4.
Bionano Genomics terminates $200M ATM equity facility with Cowen, effective Feb 14, 2025
Terminated Sales Agreement with Cowen and Company effective Feb 14, 2025.
Bionano Genomics effects 1-for-60 reverse stock split effective Jan 24, 2025
Reverse stock split at ratio 1:60, effective 5:00 p.m. ET on January 24, 2025.
Bionano Genomics stockholders approve reverse stock split (1:25-1:75) and warrant share issuance
At Jan 15 special meeting, stockholders approved issuance of up to 19,762,226 shares upon exercise of Series C/D warrants.
Bionano reports preliminary Q4 rev $7.9-8.1M (down ~25% YoY); FY rev $30.5-30.7M (down ~15%)
Preliminary Q4 2024 revenue $7.9-8.1M, down ~25% from Q4 2023 due to discontinued clinical service products.
Bionano Genomics raises $10M in registered direct offering of ~39.7M shares and warrants
Aggregate gross proceeds of ~$10M from sale of 22.9M common shares and 16.78M pre-funded warrants at $0.252/unit.
Amendment defers December 2024 redemption; monthly payments cut from $1M to $500k for Jan-Jul 2025, then rise to $1.375M from Aug 2025.
Bionano Genomics stockholders approve issuance of up to 35M shares upon warrant exercise
Vote passed: 22.9M for, 6.2M against, 1.4M abstentions, no broker non-votes.
Bionano Q3 revenue $6.1M (-35% YoY); GAAP gross margin -139% on $9.8M impairment; cash burn down
Revenue $6.1M (-35% YoY); core product/software sales $6.6M offset by $0.5M receivable write-down from discontinued clinical services.
Issued 9,881,113 shares of common stock and Series C/D warrants to purchase up to 9,881,113 shares each at $0.3039 per share.
Bionano lowers Q3 revenue guidance to $6.5-6.8M from $7.9-8.9M; cash $23.3M
Preliminary Q3 revenue $6.5-6.8M, down from prior guidance of $7.9-8.9M.
Bionano cuts workforce 45%, lowers revenue guidance to $32-36M, CFO departs
Reduction of ~84 employees (45% of workforce); expects $25-30M annual cost savings starting Q4 2024.
Bionano Q2 revenue $7.8M (-10% YoY); FY2024 guidance $36-40M; retires $15.3M notes
Q2 2024 revenue $7.8M, down 10% YoY; GAAP gross margin 33% vs 27% in Q2 2023.
Bionano Genomics receives Nasdaq notice for bid price below $1.00; 180-day cure period
Nasdaq notified Bionano on July 12, 2024 that its stock closed below $1.00 for 30 consecutive trading days.
17.5M shares/equivalents sold at $0.571/share for gross proceeds of ~$10M.
Elected Christopher Twomey, Yvonne Linney, and Aleksander Rajkovic as Class III directors until 2027.
Bionano raises $18M via convertible debt, retires High Trail Note, warns of going concern
Issued $20M principal senior secured convertible debentures (11% interest, due 2026) plus 2.25M shares for $18M gross proceeds.
As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company’s Chairman of the Board, as the Company’s Interim Chief Executive Officer.
On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately.
On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024
the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.
Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the Company, effective September 18, 2024.
Max materiality 0.85 · Median 0.68 · Most common event other_material